Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
1. A method for reducing the severity of flu-like symptoms associated with treating a patient having multiple sclerosis with intramuscularly administered interferon-β-1a, comprising:
providing a kit comprising interferon-β-1a in lyophilized form in a vial, interferon-β-1a in liquid form in a pre-filled syringe, and interferon-β-1a in liquid form in a pre-filled pen;
administering 7.5 micrograms of interferon-β1a to the patient intramuscularly in week one;
administering 15 micrograms of interferon-β1a to the patient intramuscularly in week two;
administering 22.5 micrograms of interferon-β1a to the patient intramuscularly in week three; and
administering 30 micrograms of interferon-β1a to the patient intramuscularly in week four and each week thereafter,
thereby reducing severity of flu-like symptoms experienced by the patient, wherein the severity of flu-like symptoms experienced by the patient is reduced at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a throughout an eight week period which includes once a week intramuscular administration of 30 micrograms of interferon-β-1a to the patient in weeks four through eight when compared to the severity of flu-like symptoms at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a to a patient having multiple sclerosis according to:
(i) a second schedule comprising once a week intramuscular administration of 30 micrograms of interferon-β-1a to the patient having multiple sclerosis for eight weeks; and
(ii) a third schedule comprising intramuscular administration of 7.5 micrograms of interferon-β-1a to the patient in weeks one and two, intramuscular administration of 15 micrograms of interferon-β-1a to the patient in weeks three and four, intramuscular administration of 22.5 micrograms of interferon-β-1a to the patient in weeks five and six and intramuscular administration of 30 micrograms of interferon-β-1a to the patient in week seven and each week thereafter.
2. The method of claim 1 , wherein fever, muscle aches, chills, sweating, fatigue, headache, and/or malaise in said patient are reduced.
3. The method of claim 1 , further comprising administration of an analgesic or anti-inflammatory drug, or a mixture thereof.
4. The method of claim 3 , wherein the drug is a steroid.
5. The method of claim 3 , wherein the drug is a non-steroidal anti-inflammatory agent.
6. The method of claim 3 , wherein the drug is acetaminophen.
7. The method of claim 3 , wherein the drug is ibuprofen.
8. The method of claim 1 , wherein the flu-like symptoms are reduced by at least 40% at 4-6 hours post-injection.
9. The method of claim 1 , wherein the flu-like symptoms are reduced by at least 10% at 12-15 hours post-injection.
10. The method of claim 1 , further comprising providing a vial adapter.
11. The method of claim 1 , wherein the pre-filled pen comprises an auto-injector.
12. The method of claim 1 , further comprising a needle stick prevention device.
13. The method of claim 12 , wherein the needle-stick prevention device comprises a needle shield.
14. The method of claim 13 , wherein the shield is activated manually by the patient.
15. The method of claim 13 , wherein the shield is automated.
16. The method of claim 15 , wherein the automated shield is activated by the patient.
17. The method of claim 15 , wherein the needle is automatically shielded without any action by the patient.
18. The method of claim 15 , wherein the needle is shielded without any action by the patient.
19. The method of claim 1 , wherein the kit further comprises a dose-limiting titration device.